Please assess the completion status of the following clinical trial:

Trial Title: A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males in good general health and at least 50 years of age, with symptoms of moderate to severe benign prostatic hyperplasia.~Exclusion Criteria:~* Medical conditions that would confound the efficacy evaluation.~* Medical conditions in which it would be unsafe to use an alpha-blocker.~* The use of concomitant drugs that would confound the efficacy evaluation.~* The use of concomitant drugs that would be unsafe with this alpha-blocker.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Silodosin (Type: EXPERIMENTAL): Silodosin 8 mg once daily with food
- placebo (Type: PLACEBO_COMPARATOR): Matching Placebo capsule once daily with food

Based on this trial design, predict the completion outcome and termination type (if applicable).